Pennsylvania’s Medical Marijuana Act (the “Act”) legalized the use of medical marijuana as of April 2016. Initially, the Act permitted the use of medical marijuana to treat 17 serious medical conditions when certified as such by a properly credentialed healthcare provider. The list included conditions such as cancer, HIV/AIDS, Parkinson’s disease, neurodegenerative diseases, and terminal illnesses. Since 2016, however, the Act’s list of qualifying conditions has expanded and now covers 23 conditions, including anxiety.

At the time that the Act was amended to include anxiety as a covered condition, approximately 19 percent of U.S. adults had experienced anxiety disorders in the prior year. These numbers appear to be on the rise, likely due at least in part to the COVID-19 pandemic. In April 2020, the National Center for Health Statistics partnered with the Census Bureau to implement the Household Pulse Survey, a 20-minute online survey designed to assess the impact of the coronavirus pandemic on mental health. This survey reveals that between April 23, 2020 and July 21, 2020, nearly 32 percent of adults reported symptoms of anxiety disorder. As a benchmark for comparison, the CDC points out that the National Health Interview Survey indicated that only 8.2 percent of adults aged 18 and over reported symptoms of anxiety disorder between January and June of 2019.
Continue Reading Pennsylvania medical marijuana use on the rise in times of COVID-19